If you are considering robotic prostate surgery, you may want to know its “success rate”. However, there is no single percentage because success can mean controlling the cancer, keeping PSA low, avoiding further treatment or maintaining urinary and sexual function.
Your individual outcome depends on your cancer’s stage and grade, PSA level, surgical margins and whether lymph nodes are involved. Published studies report encouraging long-term outcomes, but results vary depending on the patients treated and how success is measured.
Is There One Success Rate for Robotic Prostate Surgery?
There is no single success rate that applies to everyone having robotic prostate surgery. Your outcome depends on factors such as your cancer’s grade, stage, PSA level and whether it has spread beyond the prostate.
Doctors use several measures, including PSA recurrence, prostate cancer-specific survival, metastasis-free survival and surgical margins. These figures answer different questions, so your surgeon should interpret them alongside your individual cancer characteristics rather than relying on one percentage.
What Do Published Robotic Prostate Surgery Figures Show?
Long-term studies show strong cancer control after robot-assisted radical prostatectomy, particularly for selected localised prostate cancer. You should treat the figures below as a guide, as each study involved different patients and follow-up periods.
| Study or dataset | Outcome | Follow-up | Reported result |
| 2017 RARP meta-analysis | Biochemical recurrence-free survival | 5 years | 80% |
| 4-study CSS analysis | Prostate cancer-specific survival | 5 years | 97% |
| 5-study BCRFS analysis | Biochemical recurrence-free survival | 10 years | 79% |
| Large European RARP cohort | Biochemical recurrence-free survival | Median 10.5 years | 81.8% |
| Same European cohort | Prostate cancer-specific survival | Median 10.5 years | 98.5% |
| Same European cohort | Free from salvage treatment | Median 10.5 years | 87.5% |
| Long-term RARP series | Biochemical recurrence-free survival | 10 years | 73.1% |
| Same long-term series | Metastasis-free survival | 10 years | 97.5% |
| Same long-term series | Prostate cancer-specific survival | 10 years | 98.8% |
| UK ProtecT prostatectomy group* | Prostate cancer-specific survival | 15 years | 97.2% |
Long-term studies show encouraging results after prostate cancer surgery, but you should not view one figure as the overall “success rate”. Five-year freedom from PSA recurrence may be around 80%, while prostate cancer-specific survival can approach 98%, depending on your cancer’s grade, stage, PSA and surgical margins.
Evidence Note
Long-term studies show that robot-assisted radical prostatectomy can provide durable cancer control in appropriately selected patients, but they also demonstrate why one overall ‘success rate’ is misleading. A 2017 meta-analysis reported pooled biochemical recurrence-free survival of 80% at five years and 79% at ten years, while five-year prostate cancer-specific survival was 97%.
These outcomes varied according to factors including pre-operative PSA, tumour grade, pathological stage, surgical margins and lymph-node involvement. Individual long-term cohorts have also reported prostate cancer-specific survival above 98%, but these results reflect selected patient populations and specialist centres and should not be used to predict an individual result.
What Does Cancer Control Mean After Surgery?
The aim of radical prostatectomy is to remove your prostate and the cancer with curative intent. After radical prostatectomy, your PSA is expected to fall to a very low or undetectable level, and regular PSA testing is used to look for evidence of recurrence.
A rising PSA can suggest that cancer cells remain, but it does not automatically mean the cancer has spread or that you will develop symptoms. Some men stay well for years, while others may benefit from additional treatment such as salvage radiotherapy.
How Much Does Cancer Stage Affect the Success Rate?
Your cancer stage strongly affects your outlook, with surgery generally offering the best chance of long-term control when the cancer is confined to your prostate. Survival figures also show that prognosis can vary significantly depending on the stage at diagnosis.
| Stage at diagnosis | Approximate five-year net survival for prostate cancer in England |
| Stage 1 | Almost 100% |
| Stage 2 | Almost 100% |
| Stage 3 | Around 95% |
| Stage 4 | Around 50% |
These figures are not specific to robotic surgery, but they show why your cancer stage matters. Cancer confined to the prostate generally offers a more favourable chance of long-term disease control than cancer that has spread beyond the prostate.
How Does Prostate Cancer Grade Affect Your Chances of Success?
Your Grade Group helps show how aggressive your prostate cancer may be, with higher grades generally carrying a greater risk of recurrence after surgery. Your surgeon will consider your grade alongside your stage, PSA level and other cancer features.
Robotic surgery can still be an option for selected men with higher-grade cancer, but you may have a greater chance of needing additional treatment later. When discussing success rates, ask whether the figures apply to your specific Grade Group.
Why Does Your PSA Level Before Surgery Matter?
Your PSA level helps your surgeon assess how extensive your prostate cancer may be, although it is not a perfect measure on its own. Higher PSA levels can be linked with a greater risk of more significant disease, so your consultant will consider your PSA alongside your MRI, biopsy Grade Group and cancer stage.
After surgery, PSA becomes an important way to monitor your cancer control. If it becomes very low or undetectable and stays that way, this is generally a reassuring sign that your treatment is working.
What Is a Positive Surgical Margin and Does It Mean Surgery Failed?
A positive surgical margin means cancer cells are found at the edge of the removed tissue. It can increase your risk of recurrence, but it does not mean your surgery has failed.
- Margin result: Your pathology report shows whether cancer reaches the edge of the removed tissue.
- Recurrence risk: A positive margin may increase the chance of your PSA rising later.
- Other factors: Your Grade Group, cancer stage and post-operative PSA also affect your outlook.
- Further treatment: Some people may need additional monitoring or treatment depending on their results.
Your surgeon will interpret the margin alongside your other pathology findings. This gives you a clearer picture of your individual cancer control.
How Do Lymph Nodes and Seminal Vesicle Involvement Affect Results?
If your final pathology shows cancer in the seminal vesicles or pelvic lymph nodes, your risk of recurrence is generally higher than if the cancer was confined to the prostate. Your surgeon will consider these findings alongside your Grade Group, surgical margins and PSA after surgery when assessing your outlook.
This is why a general robotic surgery “success rate” can be misleading. If you have higher-risk disease, surgery may be the first part of your treatment, with additional treatments such as radiotherapy or hormone therapy considered if needed.
What Can UK Research Tell You About Long-Term Cancer Survival?
The UK ProtecT trial reported estimated prostate cancer-specific survival of 97.2% at 15 years in men assigned to prostatectomy. However, the trial mainly included men with PSA-detected localised disease and the operations were performed during a period before robot-assisted prostatectomy became the dominant surgical approach.
The study shows that appropriately selected men with localised prostate cancer can have very high long-term cancer-specific survival after surgery. Your individual outlook will still depend on your cancer’s stage, grade and other features.
What Do UK Figures Show About Complications After Prostatectomy?
UK audit data show that complications and readmissions can occur after radical prostatectomy, although these figures are not specific to robotic surgery. In 2023–24, 12% of men in England and 14% in Wales had an emergency readmission within 90 days.
| Measure | England | Wales | Audit period |
| Emergency readmission within 90 days after radical prostatectomy | 12% | 14% | Surgery Apr 2023–Mar 2024 |
| GU complication requiring procedural/surgical intervention within 2 years | 6% | 11% | Surgery Sep 2021–Aug 2022 |
The latest audit reported centre-level 90-day readmission rates ranging from 5% to 25% in England and 0% to 33% in Wales. This does not mean the surgery failed, but it shows why you should consider both cancer control and safety when assessing surgical outcomes.
Is Recovering Urinary Continence Part of the Success Rate?
Yes. You may see successful surgery as both controlling your cancer and helping you regain good bladder control. Leakage is common early on, but it often improves over the following weeks and months.
Your recovery depends on factors such as your age, urinary function and surgical technique. Because studies use different definitions of continence, your surgeon’s own results may give you a more useful guide.
What About Erectile Function After Robotic Prostate Surgery?
Erectile recovery is an important outcome, but your chances depend on factors such as your age, erections before surgery and whether the nerves can safely be preserved. If your cancer is close to these nerves, your surgeon may need to remove some nerve tissue to achieve good cancer control.
Recovery can take time, and you may need treatments such as tablets or other erectile rehabilitation. When comparing success rates, check whether the figures reflect patients with similar age, pre-operative function and nerve-sparing surgery to yours.
Is Robotic Surgery More Successful Than Open Prostate Surgery?
Robot-assisted prostatectomy has well-established peri-operative advantages over open surgery in areas such as blood loss, transfusion risk and hospital stay. Comparative evidence for functional and oncological outcomes is more mixed: some recent analyses report advantages for robotic surgery in biochemical recurrence or functional recovery, while others find no important difference in long-term oncological outcomes. Robotic surgery should therefore not be presented as guaranteeing better cancer survival.
Your cancer characteristics, surgeon and centre experience and the quality of your overall care all influence outcome, so the surgical platform should not be considered in isolation. The robot is a tool; it is your surgical team that uses it to make clinical decisions.
How Often Is Further Treatment Needed After Robotic Surgery?
Some men need further treatment if their PSA rises or their cancer has higher-risk features. One European cohort reported salvage-treatment-free survival of 87.5% at a median follow-up of 10.5 years.
Additional treatment may include radiotherapy or hormone therapy. Needing further treatment does not necessarily mean your surgery was unsuccessful.
How Can Your Personal Success Rate Be Estimated?
Your individual outlook is more useful than a general success rate. Your team will consider your PSA, Grade Group, MRI findings and cancer stage before surgery, then use your final pathology and post-operative PSA to refine the assessment.
These factors can show whether the cancer was confined to the prostate, whether margins or lymph nodes were involved and how likely recurrence may be. Risk-prediction tools can then help your specialist give you a more personalised estimate.
UK Guidance Note
NICE recommends discussing active surveillance, radical prostatectomy and radical radiotherapy according to a person’s prostate-cancer risk and individual circumstances. Robot-assisted surgery is a surgical approach to radical prostatectomy, but NICE does not define treatment success using one universal percentage.
NICE recommends checking PSA after radical treatment no earlier than six weeks after treatment, at least every six months for the first two years and then at least annually. Long-term PSA monitoring is therefore an important part of assessing cancer control after prostatectomy.
What Should You Ask Your Surgeon About Their Success Rates?
When discussing robotic prostate surgery, ask what your surgeon means by “success”. This could refer to cancer control, negative margins, continence, erectile function or avoiding further treatment, so the definition matters.
You can also ask whether the figures come from their own patients, how outcomes are measured and whether results are audited. Most importantly, ask how your PSA, Grade Group and cancer stage affect your own expected outcome.
Myth vs Fact
| Myth | Fact |
| Robotic prostate surgery has one standard success rate. | No. Cancer recurrence, cancer-specific survival, continence, erectile function and freedom from further treatment are different outcomes. |
| A 98% cancer-specific survival rate means 98% of patients never have recurrent cancer. | No. Cancer-specific survival and biochemical recurrence-free survival measure very different outcomes. |
| A positive surgical margin means surgery has failed. | No. It increases recurrence risk but does not mean that cancer will definitely return. |
| Robotic surgery guarantees better cancer survival than open surgery. | No. Robotic surgery has important minimally invasive benefits, but comparative oncological evidence is more complex and the platform alone does not determine outcome. |
| A rising PSA always means metastatic prostate cancer. | No. Biochemical recurrence can occur before any metastasis is detectable, and further assessment determines whether additional treatment is needed. |
Key Takeaways
- There is no single success percentage for robotic prostate surgery because cancer control, PSA recurrence, survival, continence and erectile function measure different outcomes.
- Long-term RARP studies report high cancer-specific survival, but biochemical recurrence-free survival is lower and varies substantially according to cancer risk and patient selection.
- Your PSA, Grade Group, pathological stage, surgical margins, seminal-vesicle involvement and lymph-node status are important predictors of your individual outcome.
- UK ProtecT results show excellent long-term cancer-specific survival after prostatectomy for localised disease, but they are not robotic-surgery-specific figures.
- Higher surgeon and hospital procedure volumes have been associated with some better radical-prostatectomy outcomes, although volume alone does not guarantee an individual result.
- PSA monitoring after surgery remains essential because recurrence can initially be detected biochemically before it causes symptoms. NICE recommends regular long-term PSA follow-up after radical treatment.
Frequently Asked Questions
1. What is the success rate of robotic prostate surgery?
There is no single success rate because outcomes depend on cancer control, PSA levels, urinary continence and erectile function. Your cancer stage, grade and other factors also influence your individual results.
2. Is robotic prostate surgery effective for prostate cancer?
Yes, robotic radical prostatectomy can provide strong long-term cancer control, particularly when prostate cancer is localised. Your individual prognosis depends on the characteristics of your cancer.
3. Can prostate cancer return after robotic surgery?
Yes, prostate cancer can sometimes return after surgery, usually identified through a rising PSA level. The risk depends on factors such as cancer stage, Grade Group, PSA and surgical margins.
4. Does robotic surgery improve cancer survival?
Robotic surgery can provide effective cancer control, but studies generally show similar cancer outcomes compared with open prostatectomy. Your cancer characteristics and surgical team remain important factors.
5. How successful is robotic prostate surgery for urinary continence?
Urinary leakage is common shortly after surgery but often improves over the following weeks and months. Recovery varies depending on factors such as age, urinary function before surgery and surgical technique.
6. What are the chances of erectile function recovery?
Erectile recovery depends on your age, erections before surgery and whether nerve-sparing surgery is possible. Recovery can take months or longer and may require additional treatment or rehabilitation.
7. Can you need further treatment after robotic prostate surgery?
Yes, some men may need additional treatment such as radiotherapy or hormone therapy if their PSA rises or the cancer has higher-risk features. Needing further treatment does not necessarily mean the surgery failed.
8. Does surgeon experience affect robotic prostate surgery outcomes?
Yes, surgeon experience may influence factors such as surgical margins, complications and functional recovery. It is worth asking how regularly your surgeon performs robotic radical prostatectomy.
9. How long does robotic prostate surgery take to recover from?
Initial recovery often takes several weeks, although urinary and sexual function can take considerably longer to recover. Your recovery time depends on your operation, general health and whether complications occur.
10. How can you find out your personal success rate?
Your surgeon can assess your individual outlook using your PSA, Grade Group, MRI findings, cancer stage and final pathology. These factors provide a more meaningful estimate than a general robotic surgery success percentage.
Final Thoughts: Understanding Your Robotic Prostate Surgery Results
Robotic prostate surgery can offer effective long-term cancer control, particularly when your prostate cancer is diagnosed while it remains localised. However, there is no single success rate that can predict your individual outcome. Your PSA, Grade Group, cancer stage, surgical margins, lymph-node involvement and overall health can all influence your results.
If you are considering robotic prostate surgery in London and would like specialist advice, you can contact our team to discuss your options and arrange a consultation tailored to your individual needs.
References:
- Wang, L. et al. (2017) ‘Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis’, International Urology and Nephrology, 49(6), pp. 995–1005. Available at: https://pubmed.ncbi.nlm.nih.gov/28238148/
- Rajan, P. et al. (2018) ‘Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up’, European Urology Focus, 4(3), pp. 351–359. Available at: https://pubmed.ncbi.nlm.nih.gov/28753802/
- Diaz, M. et al. (2015) ‘Oncologic outcomes at 10 years following robotic radical prostatectomy’, European Urology, 67(6), pp. 1168–1176. Available at: https://pubmed.ncbi.nlm.nih.gov/24996687/
- Hamdy, F.C. et al. (2023) ‘Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer’, New England Journal of Medicine, 388(17), pp. 1547–1558. Available at: https://pubmed.ncbi.nlm.nih.gov/36912538/
- National Institute for Health and Care Excellence (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- National Prostate Cancer Audit (2025) State of the Nation Report 2025. London: National Cancer Audit Collaborating Centre, Royal College of Surgeons of England. Published October 2025. Available at: https://www.natcan.org.uk/reports/npca-state-of-the-nation-report-2025/
- Cancer Research UK (2025) Survival for prostate cancer. Last reviewed 11 June 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/survival
- Suartz, C.V. et al. (2026) ‘Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis’, International Urology and Nephrology, online ahead of print. Available at: https://pubmed.ncbi.nlm.nih.gov/42230439/
- Van den Broeck, T. et al. (2021) ‘A systematic review of the impact of surgeon and hospital caseload volume on oncological and nononcological outcomes after radical prostatectomy for nonmetastatic prostate cancer’, European Urology, 80(5), pp. 531–545. Available at: https://pubmed.ncbi.nlm.nih.gov/33962808/